Allakos cuts 75% of workforce after chronic hives trial failure
Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following…
News
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
Akero’s cirrhosis treatment shows promise in Phase IIb study
Fortress doses first subject in Phase II CMV vaccine trial
OCT West Coast 2025: Efficient trials will help at all levels
Roche reports positive topline outcomes from DMD treatment trial
ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer
